From the present results, the PD-1/PD-L1 axis may function in immune tolerance to treatment with HDAC inhibitors especially with ambient IFN-γ, whereas HDAC inhibitors directly impair MM cell viability. The gene discussed is IFNG; the disease is Miyoshi myopathy.